pharma · Gram-negative Bacterial Infections · SARS-CoV-2 Infection
Shionogi Inc. (U.S.)
Shionogi B.V.
NovaPharmaNews editorial coverage mentioning Shionogi Inc. (U.S.) — regulatory, clinical, and market analysis.
Company details
- Status
- Public
- HQ
- Florham Park, USA
- Founded
- 2001
- Employees
- 601
- Programs
- 6
- Drugs
- 8
- Patents
- 0
News & analysis
NovaPharmaNews articles mentioning Shionogi Inc. (U.S.) — regulatory, clinical, and market coverage.
NovaPharmaNews editorial coverage mentioning Shionogi Inc. (U.S.) — regulatory, clinical, and market analysis.
FDA Approves Ensitrelvir (XOCOVA) as First Oral Option for COVID-19 Post-Exposure Prophylaxis
The FDA has approved Shionogi's ensitrelvir (XOCOVA) as the first and only oral antiviral for post-exposure prophylaxis of COVID-19. This approval addresses a critical prevention gap and introduces a convenient five-day oral regimen.
FDA Approves First Oral COVID-19 PEP Drug, Xocova
The FDA has approved Shionogi's Xocova (ensitrelvir) as the first oral post-exposure prophylaxis (PEP) for COVID-19 in adults and adolescents aged 12 years and older. The approval is based on the Phase 3 SCORPIO-PEP trial.